Introduction
============

Urothelial cell carcinoma (UCC) arises from the epithelial lining of the entire urinary tract, including the urinary bladder, ureter, and kidneys and has histologic features similar to those of cell carcinoma and is considered to have an analogous etiology [@B1]. UCC comprises more than 90% of bladder cancers in both genders. The worldwide age-standardized incidence rates (per 100,000 person/year) of bladder cancer are 9.0 for men and 2.2 for women [@B2]. In Taiwanese, bladder cancer is the ninth leading malignancy among men and the sixteenth leading malignancy among women with respective incidences of about 8.82 and 3.11. Mortality rates of bladder cancer ranked 12^th^ among all cancer deaths for men and 13^th^ among women [@B3]. The best-known risk factors are tobacco use and aromatic amine exposure, but in Taiwan, arsenic exposure in potable water and traditional herbs containing aristolochic acid are unique risk factors [@B4]-[@B7]. In addition to environmental and dietary factors, recent articles emphasized the importance of genetic factors in the development of UCC [@B8]-[@B10].

Melatonin (N-acetyl-5-methoxytryptamine) is a hormone mainly produced by the pineal gland and other organs [@B11]. It has many protective roles in several physiological areas such as circadian rhythm control, seasonal reproduction, effective endogenous free radical scavengers, and anti-apoptosis in normal cells [@B12]-[@B16]. On the contrary, melatonin also plays a vital oncostatic role in different cancers through antiproliferative, anti-invasive, anti-metastatic and proapoptotic actions, stimulation of anticancer immunity, modulation of oncogene expression, and its anti-inflammatory, antioxidant, and antiangiogenic effects [@B17]-[@B23]. Melatonin has to bind to its membranous G protein-coupled receptors to execute its cellular functions. Melatonin receptors are divided into type Ia (MTNR1A or MT~1~) and Ib (MTNR1B or MT~2~) with high binding affinity, and are largely responsible for mediating the downstream effects of melatonin [@B24]. It is widely accepted that melatonin mostly binds to MTNR1A to exhibit it anticancer effects [@B18], [@B25]. Higher MTNR1A expression was reported to be correlated with a less-malignant histologic subtype of breast cancer and a higher survival rate of breast cancer patients [@B26]. A similar correlation was also found in oral squamous cell carcinoma [@B27]. To the present, little research has been conducted into melatonin and its anticancer activity in urothelial cancer.

Among DNA sequence variations, single-nucleotide polymorphisms (SNPs) are the most common event. The variant frequency occurs in more than 1% of the population, and correlates with disease susceptibility [@B28]. Previous studies demonstrated that SNPs of *MTNR1A* were linked to several kinds of disease, including coronary artery disease, calcium nephrolithiasis, and polycystic ovary syndrome [@B29]-[@B31]. A recent study further disclosed that *MTNR1A* polymorphisms interact with environment factors to possibly raise oral-cancer susceptibility and even development of an advanced clinical stage and metastatic status [@B32]. Although associations of genetic polymorphisms of *MTNR1A* with several diseases and cancer were disclosed, knowledge of potential roles of *MTNR1A* genetic polymorphisms in susceptibility to UCC is still lacking. In this study, we intended to explore associations of polymorphisms within the *MTNR1A* gene with UCC risk and the clinicopathologic development of UCC in Taiwanese patients.

Materials and methods
=====================

Study subjects and specimen collection
--------------------------------------

In 2010\~2013, we recruited 272 patients with urothelial carcinoma, diagnosed at Taichung Veteran General Hospital in Taichung, Taiwan. There were 179 male and 93 female patients. For the control group, 272 participants with a similar male-to-female ratio and age distribution were enrolled in the study. This control group had no self-reported history of cancer at any site and was included from among those undergoing a physical examination at the hospital. Both case and control groups were reviewed for exposure history to tobacco consumption. The staging of urothelial carcinoma was according to the American Joint Committee on Cancer (AJCC) system, including the primary tumor extent, lymph node involvement, and distant organ metastasis status at the moment of disease diagnosis. Cancer cell differentiation was determined by histopathologic grading and examination by a pathologist. Tumors were classified as superficial tumors (pT0\~1, *n* = 165) or invasive tumors (pT2\~4, *n* = 107). Metastasis into lymph nodes was detected in 28 cases (10.3%), and four patients (1.5%) had distal metastasis. The study was approved by the Institutional Review Board (IRB) of Taichung Veteran General Hospital (IRB no. CF11094), and informed written consent was obtained from each participant. Whole-blood specimens collected from controls and UCC patients were placed in tubes containing ethylenediaminetetraacetic acid (EDTA), immediately centrifuged, and then stored at -80 °C.

Genomic DNA extraction and *MTNR1A* polymorphism selection
----------------------------------------------------------

Genomic DNA was extracted using a QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA) based on the manufacturer\'s instructions as previously described [@B33]. In this study, we selected three SNPs of the *MTNR1A* gene from data of the International HapMap Project as previously described [@B32]. We included -184T/C (rs2119882) in the promoter region. Rs13140012 and rs6553010, which are located in intron 1 of *MTNR1A*, were selected in this study since these two SNPs were found to modify the binding affinities of several transcription factors [@B30].

Real-time polymerase chain reaction (PCR)
-----------------------------------------

Allelic discrimination for the *MTNR1A* SNPs, rs2119882 (Assay ID: C_16100974_10), rs13140012 (Assay ID: C_31861431_10), and rs6553010 (Assay ID: C_11782809_10), were assessed using a TaqMan assay with an ABI StepOnePlus™ Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) and further analyzed with SDS vers. 3.0 software (Applied Biosystems, Foster City, CA, USA). The final volume for each reaction was 5 µL, containing 2.5 µL TaqMan Genotyping Master Mix, 0.125 µL TaqMan probe mix, and 10 ng genomic DNA. The real-time PCR consisted of initial denaturation at 95 °C for 10 min, followed by 40 cycles at 95 °C for 15 s and finally at 60 °C for 1 min.

Statistical analysis
--------------------

We compared differences in demographic characteristics between urothelial carcinoma patients and the controls using the Mann-Whitney *U*-test and Fisher\'s exact test. A goodness-of-fit *X^2^*-test was used to assess Hardy-Weinberg equilibrium (HWE) for biallelic markers. The odds ratios (ORs) and 95% confidence intervals (CIs) of the risk association of genotype frequencies with clinical and histopathological characteristics were evaluated using multiple logistic regression models. A *p* value of \<0.05 was interpreted as being statistically significant. Data were analyzed with SAS statistical software (SAS Institute, Cary, NC, USA).

Results
=======

Statistical analyses of demographic characteristics of both the case and control groups are shown in Table [1](#T1){ref-type="table"}. We found no significant differences in distributions of age, gender, or tobacco use between control participants and UCC patients. Our study population was predominantly male (62.9%) with a low proportion of smokers (25.3% in the control and 28.5% in the UCC group). Most patients (60.7%) were suffering from superficial tumors (stage pTa\~pT1).

In our recruited control group, the genotype distributions of *MTNR1A* SNPs rs2119882 and rs13140012 met the Hardy-Weinberg equilibrium in the normal controls (p=0.449, χ2 value: 0.574 and p=0.560, χ2 value: 0.340, respectively). Reconstructed linkage disequilibrium (LD) plots for the three SNPs were previously shown [@B32]. The genotype distributions and associations between UCC and gene polymorphisms of *MTNR1A* are shown in Table [2](#T2){ref-type="table"}. The distribution of *MTNR1A* genotypes revealed that the most frequent alleles were heterozygous T/C and A/T for the rs2119882 and rs13140012 loci, respectively, and homozygous A/A for the rs6553010 locus. There were no significant differences in genotype distributions or associations between urothelial carcinoma patients and the controls for the rs2119882, rs13140012, or rs6553010 SNPs (Table [2](#T2){ref-type="table"}).

As shown in Tables [3](#T3){ref-type="table"}\~5, we further analyzed genotype frequencies of individual polymorphisms with relevance to the clinicopathological status, including the cancer stage, tumor status, lymph node involvement, metastatic status, and histopathologic grading, in UCC patients. We classified UCC patients into two subgroups. In the first subgroup, patients had homozygous wild-type (WT) alleles; in the other subgroup, they had at least one polymorphic allele. No significant associations of the rs2119882 or rs13140012 gene polymorphisms with the clinicopathologic status were observed (Tables [3](#T3){ref-type="table"}, 4). However, subjects with at least one G allele of rs6553010 (AG+GG) exhibited a significantly (*p* = 0.026) higher risk of 1.768-fold (95% CI: 1.041\~2.063) of having the invasive type of UCC compared to their corresponding WT homozygotes (Table [5](#T5){ref-type="table"}).

Discussion
==========

Recently, many studies have shown that polymorphisms of *MTNR* genes (*MTNR1A* and*MTNR1B)* may affect susceptibility to several diseases, such as adolescent idiopathic scoliosis [@B34], coronary artery disease [@B29], type 2 diabetes mellitus [@B35], calcium nephrolithiasis [@B30], and polycystic ovary syndrome [@B31], and also influence the clinicopathological development of oral cancer [@B32]. In the present study, we investigated associations of variants of the *MTNR1A* gene with the UCC risk and its clinicopathologic development in a Taiwanese population.

Although *MTNR1A* gene SNPs (rs2119882, rs13140012, and rs6553010) alone did not contribute to UCC susceptibility in our study, a major finding of this study was the significant association between rs6553010 *MTNR1A* genotypes and the clinicopathological development of UCC. We observed that the frequency of the A/G and G/G combined genotypes was greater in patients with invasive UCC (44.9%) than in the controls (31.6%). This finding is similar to findings from our previous study regarding genetic polymorphisms of *MTNR1A* which alone were unable to predict the risk of oral cancer. However, after being combined with information on carcinogen exposure, a significant effect for predicting oral-cancer susceptibility was observed [@B32]. It is well-known that tobacco smoking is also the leading risk factor for developing bladder cancer. From a meta-analysis of smoking\'s effects on bladder cancer, there was an association of increased risks (odds ratios) of about 4.23 for male smokers and 1.35 for female smokers [@B36]. However, after being combined with information on carcinogen exposure, genetic polymorphisms of *MTNR1A* still could not predict UCC susceptibility in our recruited populations. This might have been due to a bias in the ratio of individuals with a smoking habit among our recruited UCC patients. In previous SNP-related studies of UCC, significantly higher ratios of individuals with a smoking habit among UCC patients than in the controls were observed [@B37]. However, we found no significantly different distributions of tobacco use between control participants and UCC patients in this study. In our future work, more UCC patients with a smoking habit should be recruited to further explore the combined effect of *MTNR1A* genetic variants and exposure to tobacco carcinogens on the risk of UCC.

Melatonin was demonstrated to exert oncostatic effects including antimetastatic activity both *in vivo* and *in vitro* in various types of malignancies via the MTNR1A receptor [@B17]-[@B19], [@B38]-[@B40]. Expression of MTNR1A in cancer cells seems to increase the efficacy of melatonin\'s oncostatic activity. The expression level of MTNR1A was inversely correlated with the invasive abilities of breast cancer cell lines [@B38]. In clinical specimens, *MTNR1A* messenger (m)RNA expression was negatively correlated with the malignancy grade of invasive ductal breast carcinomas (IDC). Moreover, higher MTNR1A expression was associated with patients\' longer overall survival (OS) in patients with estrogen receptor positive (ER^+^) breast cancers who were treated with tamoxifen. MTNR1A was recognized as an independent prognostic factor in ER^+^ tumors for OS and disease-free survival in ER^+^ tumors [@B26]. Those results indicated that the MTNR1A expression level might affect the invasive ability of breast cancer. In our study, we found that patients with one G allele of *MTNR1A* rs6553010 had higher risks of developing advanced invasive UCC than those with the WT. Although we still have no evidence that MTNR1A expression can affect the invasive ability of UCC, the intronic rs6553010 SNP is itself a functional polymorphism that exerts a direct effect on *MTNR1A* gene expression in patients with UCC. Several reports previously indicated that an intronic SNP can affect gene expressions in different diseases and also affect the susceptibility or metastasis in different cancers including UCC [@B41]-[@B45]. Previous reports indicated that some intronic polymorphic variants can induce either alternative or aberrant splicing of mRNA and further affect gene expressions [@B46]. Moreover, Esposito *et al.* indicated that another SNP, rs13140012 (A\>T mutation), in intron 1 of the *MTNR1A* gene can affect the binding affinity of several transcription factors [@B30]. The promoter activity assay in oral cancer showed that a fragment containing exon 1 and intron 1 within the *MTNR1A* gene showed remarkable transcriptional activity [@B27]. We assumed that intronic the A/G SNP rs6553010 may act alone or in combination with other yet unidentified functional variants in the gene to influence *MTNR1A* expression.

Despite our best efforts, a significant proportion of patients suffering from UCC will develop advanced disease, and we do not currently have sufficiently reliable tools to predict who these patients are. In this study, we found a significant association between the invasive UCC type and the rs6553010 A/G and G/G combined genotypes. The rs6553010 G allele may act as a risk factor. In order to precisely evaluate *MTNR1A* polymorphisms and clinicopathological development of UCC, a much-larger sample size is needed. Ultimately, we suggest that future studies of the functional activities of these polymorphisms and their effects on tumor invasion would help us understand the underlying mechanisms in UCC development.
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###### 

The distributions of demographical characteristics in 272 controls and 272 urothelial cell carcinoma patients.

  Variable                      Controls (*N*=272)   Patients (*N*=272)   *p* value
  ----------------------------- -------------------- -------------------- -----------
  **Age (yrs)**                 **Mean ± S.D.**      **Mean ± S.D.**      
                                67.79 ± 10.06        68.68 ± 12.06        *p*=0.349
  **Gender**                                                              
  Male                          181 (66.5%)          179 (65.8%)          
  Female                        91 (33.5%)           93 (34.2%)           *p*=0.856
  **Tobacco consumption**                                                 
  No                            201 (73.9%)          196 (72.1%)          
  Yes                           71 (26.1%)           76 (27.9%)           *p*=0.629
  **Stage**                                                               
  Superficial tumor (pTa-pT1)                        165 (60.7%)          
  Invasive tumor (pT2-pT4)                           107 (39.3%)          
  **Tumor T status**                                                      
  T0                                                 74 (27.2%)           
  T1-T4                                              198 (72.8%)          
  **Lymph node status**                                                   
  N0                                                 244 (89.7%)          
  N1+N2                                              28 (10.3%)           
  **Metastasis**                                                          
  M0                                                 268 (98.5%)          
  M1                                                 4 (1.5%)             
  **Histopathologic grading**                                             
  Low grade                                          39 (14.3%)           
  High grade                                         233 (85.7%)          

Mann-Whitney U test or Fisher\'s exact test was used between controls and urothelial cell carcinoma patients.

###### 

Distribution frequencies of *MTNR1A* genotypes in 272 controls and 272 urothelial cell carcinoma patients

  Variable                 Controls (*N*=272) *n* (%)       Patients (*N*=272) *n* (%)       OR (95% CI)
  ------------------------ -------------------------------- -------------------------------- ----------------------
  **rs2119882**                                                                              
  TT                       113 (41.5%)                      108 (39.7%)                      1.00
  TC                       129 (47.4%)                      119 (43.8%)                      0.965 (0.672\~1.387)
  CC                       30 (11.1%)                       45 (16.5%)                       1.569 (0.922\~2.672)
  TC+CC                    159 (58.5%)                      164 (60.3%)                      1.079 (0.766\~1.520)
  **rs2119882 Alleles**    **Controls (*N*=544) *n* (%)**   **Patients (*N*=544) *n* (%)**   
  T                        355 (65.3%)                      335 (61.6%)                      1.00
  C                        189 (34.7%)                      209 (38.4%)                      1.172 (0.915\~1.500)
  **rs13140012**                                                                             
  AA                       111 (40.8%)                      103 (37.9%)                      1.00
  AT                       122 (44.9%)                      130 (47.8%)                      1.148 (0.797\~1.654)
  TT                       39 (14.3%)                       39 (14.3%)                       1.078 (0.642\~1.810)
  AT+TT                    161 (59.2%)                      169 (62.1%)                      1.131 (0.802\~1.596)
  **rs13140012 Alleles**   **Controls (*N*=544) *n* (%)**   **Patients (*N*=544) *n* (%)**   
  A                        344 (63.2%)                      336 (61.8%)                      1.00
  T                        200 (36.8%)                      208 (38.2%)                      1.065 (0.833\~1.361)
  **rs6553010**                                                                              
  AA                       124 (45.6%)                      114 (41.9%)                      1.00
  AG                       105 (38.6%)                      103 (37.9%)                      1.067 (0.735\~1.548)
  GG                       43 (15.8%)                       55 (20.2%)                       1.391 (0.867\~2.233)
  AG+GG                    148 (54.4%)                      158 (58.1%)                      1.161 (0.827\~1.630)
  **rs6553010 Alleles**    **Controls (*N*=544) *n* (%)**   **Patients (*N*=544) *n* (%)**   
  A                        353 (64.9%)                      331 (60.8%)                      1.00
  G                        191 (35.1%)                      213 (39.2%)                      1.189 (0.930\~1.521)

The odds ratios (ORs) and with their 95% confidence intervals (CIs) were estimated by logistic regression models.

###### 

Distribution frequencies of the clinical status and *MTNR1A* rs2119882 genotype frequencies of 272 patients with urothelial cell carcinoma

  Variable                       MTNR1A (rs2119882)                                         
  ------------------------------ -------------------- ------------- ----------------------- -----------
  **Stage**                                                                                 
  Superficial tumor (pTa\~pT1)   72 (66.7%)           93 (56.7%)    1.00                    
  Invasive tumor (pT2\~pT4)      36 (33.3%)           71 (43.3%)    1.527 (0.921\~2.531)    *p*=0.100
  **Tumor T status**                                                                        
  T0                             33 (30.6%)           41 (25.0%)    1.00                    
  T1\~T4                         75 (69.4%)           123 (75.0%)   1.320 (0.769\~2.267)    *p*=0.314
  **Lymph node status**                                                                     
  N0                             99 (91.7%)           145 (88.4%)   1.00                    
  N1+N2                          9 (8.3%)             19 (11.6%)    1.441 (0.626\~3.316)    *p*=0.388
  **Metastasis**                                                                            
  M0                             107 (99.1%)          161 (98.2%)   1.00                    
  M1                             1 (0.9%)             3 (1.8%)      1.994 (0.205\~19.421)   *p*=0.545
  **Histopathologic grading**                                                               
  Low grade                      11 (10.2%)           28 (17.1%)    1.00                    
  High grade                     97 (89.8%)           136 (82.9%)   0.551 (0.262\~1.160)    *p*=0.113

OR, odds ratio; CI, confidence interval.

###### 

Distribution frequencies of the clinical status and *MTNR1A* rs13140012 genotype frequencies in 272 patients with urothelial cell carcinoma

  Variable                       MTNR1A (rs13140012)                                         
  ------------------------------ --------------------- ------------- ----------------------- -----------
  **Stage**                                                                                  
  Superficial tumor (pTa\~pT1)   69 (67.0%)            96 (56.8%)    1.00                    
  Invasive tumor (pT2\~pT4)      34 (33.0%)            73 (43.2%)    1.543 (0.926\~2.573)    *p*=0.095
  **Tumor T status**                                                                         
  T0                             29 (28.2%)            45 (26.6%)    1.00                    
  T1\~T4                         74 (71.8%)            124 (73.4%)   1.080 (0.624\~1.869)    *p*=0.784
  **Lymph node status**                                                                      
  N0                             94 (91.3%)            150 (88.8%)   1.00                    
  N1+N2                          9 (8.7%)              19 (11.2%)    1.323 (0.575\~3.046)    *p*=0.510
  **Metastasis**                                                                             
  M0                             102 (99.0%)           166 (98.2%)   1.00                    
  M1                             1 (1.0%)              3 (1.8%)      1.843 (0.189\~17.960)   *p*=0.593
  **Histopathologic grading**                                                                
  Low grade                      10 (9.7%)             29 (17.2%)    1.00                    
  High grade                     93 (90.3%)            140 (82.8%)   0.519 (0.242\~1.116)    *p*=0.089

OR, odds ratio; CI, confidence interval.

###### 

Distribution frequencies of the clinical status and *MTNR1A* rs6553010 genotype frequencies in 272 patients with urothelial cell carcinoma

  Variable                       MTNR1A (rs6553010)                                            
  ------------------------------ -------------------- ------------- -------------------------- -----------------
  **Stage**                                                                                    
  Superficial tumor (pTa\~pT1)   78 (68.4%)           87 (55.1%)    1.00                       
  Invasive tumor (pT2\~pT4)      36 (31.6%)           71 (44.9%)    **1.768 (1.068\~2.928)**   ***p*=0.026\***
  **Tumor T status**                                                                           
  T0                             32 (28.1%)           42 (26.6%)    1.00                       
  T1\~T4                         82 (71.9%)           116 (73.4%)   1.078 (0.628\~1.849)       *p*=0.786
  **Lymph node status**                                                                        
  N0                             101 (88.6%)          143 (90.5%)   1.00                       
  N1+N2                          13 (11.4%)           15 (9.5%)     0.815 (0.372-1.787)        *p*=0.609
  **Metastasis**                                                                               
  M0                             112 (98.2%)          156 (98.7%)   1.00                       
  M1                             2 (1.8%)             2 (1.3%)      0.718 (0.100-5.174)        *p*=0.741
  **Histopathologic grading**                                                                  
  Low grade                      13 (11.4%)           26 (16.5%)    1.00                       
  High grade                     101 (88.6%)          132 (83.5%)   0.653 (0.320-1.335)        *p*=0.241

OR, odds ratio; CI confidence interval.
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